OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.
OTUD5 enhances SLC7A11 stability in AML, suppressing ferroptosis and potentially contributing to treatment resistance.
Where it sits
this study against the rest of the tb-500 (thymosin beta-4 fragment) corpusSummary and findings
This study investigates the role of OTUD5 in acute myeloid leukemia (AML) progression by regulating SLC7A11 to suppress ferroptosis. OTUD5 was analyzed in AML patient samples and cell lines, with functional assays conducted following OTUD5 silencing and overexpression. The findings suggest that OTUD5 enhances SLC7A11 stability, promoting AML cell survival.
Abstract
Acute myeloid leukemia (AML) is a highly aggressive malignancy with frequent therapeutic resistance, necessitating the identification of novel molecular targets. This study aims to elucidate the role of the deubiquitinase OTUD5 in AML progression by regulating SLC7A11 to suppress ferroptosis. We analyzed OTUD5 expression in AML patient samples and cell lines using RNA sequencing and quantitative PCR. Functional roles were assessed through OTUD5 silencing and overexpression in AML cell lines (THP-1, HL-60), followed by proliferation, colony formation, and ferroptosis assays (ROS, labile Fe<sup>2 +</sup>, GSH, MDA). Co-immunoprecipitation and ubiquitination assays confirmed OTUD5-SLC7A11 interactions, while <i>in vivo</i> xenograft models validated findings. Molecular docking and transmission electron microscopy further elucidated mechanisms. OTUD5 was significantly upregulated in AML, correlating with ferroptosis suppression. OTUD5 directly interacted with and deubiquitinated SLC7A11, enhancing its stability and promoting AML cell survival. OTUD5 silencing induced ferroptosis, marked by increased labile iron, ROS, and mitochondrial damage, which was reversed by SLC7A11 overexpression or GSH supplementation. <i>In vivo</i>, OTUD5 knockdown reduced tumor growth, an effect mitigated by SLC7A11 overexpression or GSH. The OTUD5-SLC7A11 axis drives AML progression by suppressing ferroptosis, offering a novel therapeutic target to exploit ferroptosis sensitivity and overcome treatment resistance in AML.
Background
This paper addresses the role of OTUD5 in acute myeloid leukemia (AML), a malignancy known for its aggressive nature and frequent therapeutic resistance. Previous research has indicated that targeting molecular pathways involved in cell survival may offer new treatment strategies. Understanding how OTUD5 regulates SLC7A11 and ferroptosis could provide insights into potential therapeutic targets for overcoming resistance in AML.
Methods
The study utilized RNA sequencing and quantitative PCR to analyze OTUD5 expression in AML patient samples and cell lines. Functional roles were assessed through silencing and overexpression of OTUD5 in AML cell lines (THP-1, HL-60). Proliferation, colony formation, and ferroptosis assays were conducted, along with co-immunoprecipitation and ubiquitination assays to confirm interactions. In vivo xenograft models were employed to validate findings.
Results
OTUD5 was significantly upregulated in AML, correlating with ferroptosis suppression. Silencing OTUD5 induced ferroptosis, indicated by increased labile iron, ROS, and mitochondrial damage. In vivo, OTUD5 knockdown resulted in reduced tumor growth, which was mitigated by SLC7A11 overexpression or GSH supplementation.
Interpretation
The findings suggest that OTUD5 plays a critical role in AML progression by stabilizing SLC7A11 and suppressing ferroptosis. While the results are statistically significant, the clinical relevance remains uncertain as the effect sizes and translational implications require further investigation. Confounding factors include reliance on cell lines and animal models, which may not fully capture the complexity of human AML.
Key findings
- OTUD5 was significantly upregulated in AML, correlating with ferroptosis suppression.
- OTUD5 silencing induced ferroptosis, marked by increased labile iron, ROS, and mitochondrial damage.
- In vivo, OTUD5 knockdown reduced tumor growth, an effect mitigated by SLC7A11 overexpression or GSH.
Limitations
- Primarily uses cell lines and in vivo models, which may not fully represent human AML.
- Effects observed may not translate directly to clinical settings due to disease complexity.